Efimosfermin alfa (BOS-580), a long-acting FGF21 analogue, in participants with phenotypic metabolic dysfunction-associated steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2a trial.
- DOI
- 10.1016/s2468-1253(25)00067-6
- Published
- 2025 Aug
- Container
- The lancet. Gastroenterology & hepatology
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/s2468-1253-25-00067-6,
title = {Efimosfermin alfa (BOS-580), a long-acting FGF21 analogue, in participants with phenotypic metabolic dysfunction-associated steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2a trial.},
author = {Loomba R and Kowdley KV and Rodriguez J and Kim NJ and Alvarez AM and Morrow L and Jeglinski B and Clawson A and Chowdhury S and Bain G and Odrljin T},
year = {2025},
journal = {The lancet. Gastroenterology \& hepatology},
doi = {10.1016/s2468-1253(25)00067-6},
url = {https://doi.org/10.1016/s2468-1253(25)00067-6}
}RIS
TY - JOUR TI - Efimosfermin alfa (BOS-580), a long-acting FGF21 analogue, in participants with phenotypic metabolic dysfunction-associated steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2a trial. AU - Loomba R AU - Kowdley KV AU - Rodriguez J AU - Kim NJ AU - Alvarez AM AU - Morrow L AU - Jeglinski B AU - Clawson A AU - Chowdhury S AU - Bain G AU - Odrljin T PY - 2025 JO - The lancet. Gastroenterology & hepatology DO - 10.1016/s2468-1253(25)00067-6 UR - https://doi.org/10.1016/s2468-1253(25)00067-6 ER -
APA
R, L., KV, K., J, R., NJ, K., AM, A., L, M., B, J., A, C., S, C., G, B., & T, O. (2025). Efimosfermin alfa (BOS-580), a long-acting FGF21 analogue, in participants with phenotypic metabolic dysfunction-associated steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2a trial.. The lancet. Gastroenterology & hepatology. https://doi.org/10.1016/s2468-1253(25)00067-6
Source records
- pubmed · retrieved 2026-09-26T17:39:48.250Z